HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Says Still No Evidence Vitamin D Prevents Or Treats COVID-19

Executive Summary

Yet another rapid review by the UK's NICE finds insufficient evidence to support taking vitamin D to prevent or treat COVID-19. Nevertheless, the UK government is handing out free vitamin D supplements to clinically vulnerable groups in England from Janurary. 

You may also be interested in...



UK Needs Higher Daily Vitamin D Supplement Doses To Achieve Immunity Effects

Current UK government guidelines on vitamin D supplementation (400IU or 10mcg vitamin D a day) are too low to achieve immunity boosting effects, says UK expert and University of Birmingham scientist Martin Hewison. 

Digitalization Key To Sustaining COVID-Related Boost To UK Supplements Market

Thanks to coronavirus-related wellness trends, the UK's vitamins and mineral supplementns market is set to be worth $664m by the end of the year, according to Mintel. But to make sure this increased demand is here to stay, consumer health companies need to leverage the power of digital to help consumers establish long-term supplementation habits into the future. 

UK Government Backs Vitamin D COVID Benefits With Supplement Handout

By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS150823

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel